Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000902664-24-005943
Filing Date
2024-10-22
Accepted
2024-10-22 16:15:11
Documents
1

Document Format Files

Seq Description Document Type Size
1 p24-3033sc13da.htm SC 13D/A 79373
  Complete submission text file 0000902664-24-005943.txt   81243
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Subject) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-51477 | Film No.: 241386475
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116
Business Address 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116 617-867-2800
Adage Capital Management, L.P. (Filed by) CIK: 0001535978 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A